Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Cogent Biosciences (COGT) Other financing activities (2017 - 2018)

Cogent Biosciences has reported Other financing activities over the past 2 years, most recently at $1.5 million for Q2 2018.

Quarterly results put Other financing activities at $1.5 million for Q2 2018, changed N/A from a year ago — trailing twelve months through Dec 2018 was $2.1 million (changed N/A YoY), and the annual figure for FY2025 was $2.6 million, changed.
Other financing activities for Q2 2018 was $1.5 million at Cogent Biosciences, up from $563000.0 in the prior quarter.
Over the last five years, Other financing activities for COGT hit a ceiling of $1.5 million in Q2 2018 and a floor of $563000.0 in Q1 2018.